Induction alectinib or crizotinib for stage III NSCLC harboring ALK fusion: A study with 4-year follow-up
{{output}}
Background: Despite increased response and long-term benefit of anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (TKIs) in advanced non-small cell lung cancer (NSCLC) harboring ALK-fusion, the role of induction ALK-TKI... ...
